Thiotepa - Sumitomo Dainippon Pharma

Drug Profile

Thiotepa - Sumitomo Dainippon Pharma

Alternative Names: DSP 1958

Latest Information Update: 22 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Sumitomo Dainippon Pharma
  • Class Antineoplastics; Myeloablative agonists; Organothiophosphorus compounds
  • Mechanism of Action Alkylating agents; DNA synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Haematological disorders; Solid tumours

Most Recent Events

  • 01 Sep 2017 Sumitomo Dainippon Pharma initiates enrolment in a phase I trial for Solid tumours and Lymphoma (In children, In adolescents, In adults) in Japan (IV) (JapicCTI-173654)
  • 28 Jul 2017 Sumitomo Dainippon Pharma plans a phase I trial for Solid tumours and Lymphoma (In children, In adolescents, In adults) in Japan (IV) (JapicCTI-173654)
  • 07 Nov 2016 Chemical structure information added
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top